Phentermine Completed Phase 4 Trials for Obesity Treatment

Indications	Status	Purpose	Phase
DBCOND0015947 (Obesity)	Completed	Treatment	4

clinicaltrials.gov Identifier	Title	Drugs
NCT04408586	Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker	Phentermine (DB00191) Topiramate (DB00273)
NCT03779048	Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment	Phentermine (DB00191)
NCT02911818	Lifestyle Modification and Liraglutide	Liraglutide (DB06655) Phentermine (DB00191)
NCT02229214	Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects	Phentermine (DB00191) Topiramate (DB00273)
NCT01922934	A Toolbox Approach to Obesity Treatment in Primary Care	Phentermine (DB00191) Topiramate (DB00273)
NCT01834404	Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients	Phentermine (DB00191) Topiramate (DB00273)